The Alkaloid #36: Who DJs the Trip?
Who chooses the soundtrack for psychedelic therapy? An analysis of eight playlists finds only weak evidence for a shared musical arc, without testing whether the music helps patients.
Who chooses the soundtrack for psychedelic therapy? An analysis of eight playlists finds only weak evidence for a shared musical arc, without testing whether the music helps patients.
A new database describes 25,419 Fireside peer-support interactions. It offers a view of help-seeking, not a league table of drug risk or proof that support works.
Nine studies, 537 adults, and a very uncertain answer. A Cochrane review on cannabis for insomnia shows why feeling sleepy and treating insomnia need separate evidence.
A mebufotenin trial found an antidepressant signal and early discharge readiness. Its protocol still required four hours at the clinic. Those are different findings.
Indica, sativa, hybrid: familiar labels, unreliable predictions. What cannabis chemistry research can tell us—and what it cannot.
Four former psychedelic-trial participants describe life after the final visit. Their accounts raise questions about aftercare, with company involvement disclosed.
What an ageing-brain review, a mouse experiment and human blood samples can tell us about cannabinoid signalling—and what they cannot establish.
Heating THC produced 79 small-molecule breakdown products in a new lab study. What the experiment shows, what it cannot tell us, and why better testing should serve people who use cannabis.
A new US survey records health changes people attribute to five psychoactive drugs. Its small subgroups and different recall windows matter as much as the headlines.
Gabon wants a share of the ibogaine boom. New reporting exposes the distance between paying for bark and sharing the value created afterward.
Kratom leaf and concentrated 7-OH can share a name on the shelf without sharing a chemical profile. The distinction matters for safety, research and regulation.
Before a cannabis jar reaches the counter, someone grows, harvests and cures it. Massachusetts' repeal debate is also about those paychecks, the businesses behind them and the limits of promises about what comes next.